New Therapeutic Options for Migraine: The Role of Nurse Practitioners in Patient Management

Format: Webinar
Credit(s): 0.25 (15 min)
Release Date: Nov 07, 2019
Expiration Date: Feb 05, 2020
Credit Type(s):

PROGRAM OVERVIEW

Research has led to an improved understanding of the pathophysiology of migraine, as well as the subsequent development of therapeutic agents shown to improve the prevention and management of the condition. Elucidating the role of calcitonin gene-related peptide (CGRP) in the development of migraine (in particular chronic migraine) can aid clinicians in improving the management of their patients and optimizing outcomes.

This CME activity, New Therapeutic Options for Migraine: The Role of Nurse Practitioners in Patient Management, will address the integral role of nurse practitioners in migraine management, review current evidence in the diagnosis and treatment of migraine, describe the role of CGRP in migraine pathophysiology, and examine the role and placement of newly approved CGRP-targeted therapies.

AGENDA

  • Welcome and Introductions
  • Recognizing Migraine Headaches
  • Pathophysiology of Migraine: The Role of CGRP
  • Treatment of Migraine: Current, New, and Emerging Therapies
  • Q&A Session and Activity Roundup

TARGET AUDIENCE

This activity is intended for nurse practitioners, who can benefit from education on the diagnosis and treatment of patients with migraine.

EDUCATIONAL OBJECTIVES

This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

At the conclusion of this activity, participants should be able to:

  • Recognize the signs and symptoms of migraine utilizing diagnostic criteria
  • Describe the pathophysiology of migraine, including the role of calcitonin gene-related peptide (CGRP)
  • Utilize pharmacologic, nonpharmacologic, and preventive therapies to develop an individualized migraine treatment plan for each patient
  • Review clinical-trial data on the efficacy/safety of new and emerging therapeutic agents for the prevention of migraines

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of USF Health and Rockpointe. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

PHYSICIAN CREDIT DESIGNATION
USF Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSE PRACTITIONER CREDIT DESIGNATION
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.5 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19093915. This activity was planned in accordance with AANP Accreditation Standards and Policies.

FACULTY

Jack Schim, MD Co-Director The Headache Center of Southern California Carlsbad, CA
Jack Schim, MD is board-certified in neurology and headache medicine. He is Co-Director of the Headache Center of Southern California, and has been a clinical investigator in multiple clinical trials, including research on headache, pain, movement disorders, stroke, and spasticity. He trained at the University of California San Diego, where he has been an Assistant Clinical Professor, Voluntary in the Department of Neuroscience. He is in private practice in San Diego, CA. When not seeing patients, Dr. Schim enjoys surfing and photography.
Christina Treppendahl, FNP-BC, AQH, MHD Founder and Director The Headache Center and The Headache Center Institute Ridgeland, MS
Christina Treppendahl, FNP-BC, AQH, MHD is the Founder and Director of the Annual Mississippi Headache Symposium, Headache Center Institute, Headache Center Fellowship, Headache Neurology Research Institute, and Mississippi’s only headache specialty clinic, the Headache Center. Profits from the symposium are donated to the Headache Center Institute, a nonprofit dedicated to practitioner training and provider education to improve patient outcomes. She was chosen as one of 30 world experts in headache medicine to speak at the 2020 World Migraine Summit. Ms. Treppendahl was awarded a Certificate of Added Qualification in Headache Medicine from the National Headache Foundation in 2016, and she was awarded America’s Top Nurse Practitioner in 2018. She is currently enrolled in her second year of the Master of Headache Disorders programme at the University of Copenhagen in Denmark, where she studies with her mentors, including 2019 keynote speaker, Dr. Rigmor Jensen. Ms. Treppendahl has served as the Principal Investigator for more than ten national and international clinical trials for headache treatment therapies. She has co-authored a publication with several other clinicians and travels the country presenting certified education on new therapeutic options for migraine at regional American Association of Nurse Practitioners (AANP) meetings.

PROVIDER

Jointly provided by USF Health and Rockpointe
.

In collaboration with Health Union

SUPPORTER

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

RELATED COURSES

A.C.T. N.O.W.: A Challenge To Neurologists to Open the Window-of-Opportunity for Patients with Early Alzheimer’s Disease

Learn More

A.C.T. N.O.W.: A Challenge To Neurologists to Open the Window-of-Opportunity for Patients with Early Alzheimer’s Disease

Learn More

A.C.T. N.O.W.: A Challenge To Neurologists to Open the Window-of-Opportunity for Patients with Early Alzheimer’s Disease

Learn More
This entry was posted in . Bookmark the permalink.

Follow Us :

Follow Us :

© 2021 Rockpointe Corporation

Privacy Policy

© 2021 Rockpointe Corporation

Privacy Policy